At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
Galantamine +1 moredrug
Likely dose
Galantamine 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
In Brief
A clinical study evaluating Galantamine and placebo for Cocaine Abuse. Completed, enrolled 34 participants across 1 site.
Detailed Summary
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedFeb 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedFeb 5, 2008
Enrollment StartJun 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.4 years ago
Interventions
Galantaminedrug
Galantamine 8 mg/day
placebodrug
sugar pill